{
    "clinical_study": {
        "@rank": "23457", 
        "acronym": "FAMYLY", 
        "arm_group": {
            "arm_group_label": "OMEGAVEN - Daunorubicin - Cytarabine", 
            "arm_group_type": "Experimental", 
            "description": "If  WBC \u2265 30 G/L, chemotherapy the induction cycle :\nDaunorubicin 60 mg/m\u00b2/day IV on D1, D2, and D3\nCytarabine 200 mg/m\u00b2/day  D1 to D7\nOMEGAVEN\u00ae 2 ml/kg  D1 to D9,\nIf  WBC \u2264 30 G/L, OMEGAVEN during 48 hours\nInduction cycle :\nOMEGAVEN\u00ae 2 ml/kg  D-2 to D7 Daunorubicin 60 mg/m\u00b2/day IV  on D1, D2, and D3\n- Cytarabine 200 mg/m\u00b2/day IV D1 to D7\nbone marrow aspirate at D15: If BM blasts are > 5% or if  second induction course :\nDaunorubicin 35 mg/m\u00b2/day IV  D17 and D18\nOMEGAVEN\u00ae 2 ml/kg\nCytarabine 1000 mg/m\u00b2/12h IV  on D17, D18, and D19\nFor all patients: G-CSF 5 \u00b5g/kg/day subcutaneously from D21 to hematopoietic recovery (PMN > 1 G/L or > 0.5 G/L during 3 days).\nConsolidation will be administered at investigator's discretion"
        }, 
        "brief_summary": {
            "textblock": "Pilot study of the efficacy and tolerance of the adjunction of a Fish oil emulsion to\n      daunorubicin and cytarabine chemotherapy   for the treatment of Acute MYeloblastic Leukemia\n      of Younger patients (under 61 years) with high-risk cytogenetics."
        }, 
        "brief_title": "Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myeloid Leukemia (AML)", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Adjunction of a Fish oil emulsion  OMEGAVEN to daunorubicin and cytarabine chemotherapy  for\n      the treatment of Acute MYeloblastic Leukemia of Younger patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient between 18 and 60 years old (less than 61 years old)\n\n          -  With newly diagnosed with AML according to WHO classification:\n\n          -  With 20% or more blasts in the bone marrow\n\n          -  Patients with history of tumors other than myeloproliferative disorders or\n             myelodysplastic syndromes, having received chemotherapy and/or radiotherapy without\n             previous history of myelodysplastic syndromes are eligible for the present study\n\n          -  High-risk cytogenetics defined as one the following abnormalities : 5/5q-, 7/7q-,\n             t(6,9), 11q23 abnormality excluding t(9;11), 3q abnormality,complex karyotype (>3\n             abnormalites)\n\n          -  Left ventricular ejection fraction (LVEF) > 50% on echocardiography or multigated\n             acquisition (MUGA) scan or similar radionuclide angiographic scan.\n\n          -  Adequate liver function (all of the following) except if secondary to the leukemia:\n\n        Total bilirubin below 1.5 x upper limit of normal (ULN),  AST and ALT below 2.5 x ULN ,\n        gamma-GT below 2.5 x ULN,\n\n          -  Adequate kidney function (all of the following): Serum creatinine below 1.5 x ULN,\n             Creatinine clearance above 50 mL/min (Cockroft and Gault formula)\n\n          -  ECOG performance status < or = 2.\n\n          -  Absence of any psychological, familial, sociological or geographical condition\n             potentially hampering compliance with the study protocol and follow-up schedule.\n\n          -  The patient must give written (personally signed and dated) informed consent before\n             completing any study-related procedure which means assessment or evaluation that\n             would not form part of the normal medical care of the patient.\n\n          -  Affiliated to the French Social Security (Health Insurance).\n\n        Exclusion Criteria:\n\n          -  Previous allogeneic stem cell transplantation.\n\n          -  Pre-existing aplastic anemia\n\n          -  Presence of favourable cytogenetics with t(8;21), t(15;17), or inv(16)\n\n          -  Previous history of MDS or myeloproliferative neoplasm\n\n          -  Uncontrolled active infection.\n\n          -  History of arrythmia.\n\n          -  Cardiac toxicity induced by another anthracycline administration\n\n          -  Maximum cumulative dose reached for any anthracyclin\n\n          -  Allergy to cytarabine, daunorubicin, fish or egg proteins10. Significant neurologic\n             (grade > 2) or psychiatric disorder, dementia or seizures.\n\n          -  Clinical symptoms suggesting active central nervous system leukemia.\n\n          -  Degenerative or toxic encephalopathy\n\n          -  Severe complications of leukemia such as:Uncontrolled bleeding, Pneumonia with\n             hypoxia or shock\n\n          -  Prior total body irradiation > 10 Gy.\n\n          -  Known active HIV, Hepatitis B or C infection\n\n          -  Pregnancy or breastfeeding\n\n          -  Concomitant anti-amarile vaccination (yellow fever)\n\n          -  Concurrent treatment with any other anti-cancer therapy except Hydroxyurea"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "61 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999413", 
            "org_study_id": "FAMYLY"
        }, 
        "intervention": [
            {
                "arm_group_label": "OMEGAVEN - Daunorubicin - Cytarabine", 
                "description": "AML Study treatment induction phase", 
                "intervention_name": "OMEGAVEN", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "OMEGAVEN - Daunorubicin - Cytarabine", 
                "description": "AML Study treatment induction phase", 
                "intervention_name": "Daunorubicin", 
                "intervention_type": "Drug", 
                "other_name": "Cerubidine"
            }, 
            {
                "arm_group_label": "OMEGAVEN - Daunorubicin - Cytarabine", 
                "description": "AML Study treatment induction phase", 
                "intervention_name": "Cytarabine", 
                "intervention_type": "Drug", 
                "other_name": "Aracytine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Daunorubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "AML", 
            "high-risk cytogenetics", 
            "younger patients", 
            "Induction treatment", 
            "OMEGAVEN"
        ], 
        "lastchanged_date": "November 26, 2013", 
        "link": {
            "description": "Goelams site", 
            "url": "http://infodoc.inserm.fr/goelams"
        }, 
        "location": {
            "contact": {
                "email": "ariane.mineur@chu-bordeaux.fr", 
                "last_name": "Ariane MINEUR, Mrs", 
                "phone": "+33 5 57 62 31 08"
            }, 
            "contact_backup": {
                "email": "r.delepine@chu-tours.fr", 
                "last_name": "Roselyne DELEPINE, Mrs", 
                "phone": "+33(0)2 47 47 37 98"
            }, 
            "facility": {
                "address": {
                    "city": "Tours", 
                    "country": "France", 
                    "zip": "37044"
                }, 
                "name": "Emmanuel GYAN"
            }, 
            "investigator": [
                {
                    "last_name": "Emmanuel GYAN, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Mathilde HUNAULT, MD PD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Arnaud PIGNEUX, MD PD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Romain GUIEZE, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Claude Eric BULABOIS, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jacques DELAUNAY, MD PD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Vincent DELWAIL, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Bruno LIOURE, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Carole BONMATI, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Study of the Efficacy and Tolerance of the Adjunction of a Fish Oil Emulsion to Daunorubicin and Cytarabine Chemotherapy for the Treatment of Acute MYeloblastic Leukemia of Younger Patients (Under 61 Years) With High-risk Cytogenetics", 
        "overall_contact": {
            "email": "emmanuel.gyan@univ-tours.fr", 
            "last_name": "Emmanuel GYAN, MD", 
            "phone": "+33 2 47 47 37 12"
        }, 
        "overall_contact_backup": {
            "email": "ariane.mineur@chu-bordeaux.fr", 
            "last_name": "Ariane MINEUR, Mrs", 
            "phone": "+33 5 57 62 31 08"
        }, 
        "overall_official": {
            "affiliation": "Groupe Ouest Est d'Etude des Leuc\u00e9mies et Autres Maladies du Sang GOELAMS", 
            "last_name": "Emmanuel GYAN, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of patients incomplete response rate after the adjunction of a Fish oil emulsion to daunorubicin and cytarabine chemotherapy  for the induction of untreated AML", 
            "measure": "response to study treatment", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999413"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of patients with side effects during and after the admistration of a Fish oil emulsion with daunorubicin and cytarabine chemotherapy for the induction of untreated AML", 
                "measure": "Tolerance", 
                "safety_issue": "Yes", 
                "time_frame": "4 months"
            }, 
            {
                "description": "Daily quantification of peripheral blasts by flow cytometry during  the adjunction of a Fish oil emulsion to daunorubicin and cytarabine chemotherapy", 
                "measure": "Efficacy on peripheral blasts decrease", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Measure of plasma concentration of daunorubicin and cytarabine administered together with a fish oil emulsion", 
                "measure": "pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }
        ], 
        "source": "Groupe Ouest Est d'Etude des Leuc\u00e9mies et Autres Maladies du Sang GOELAMS", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Groupe Ouest Est d'Etude des Leuc\u00e9mies et Autres Maladies du Sang GOELAMS", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}